Should We Use Gene Editing to Create Super Babies?
By Katie Hasson,
The New York Times Upfront
| 02. 17. 2025
A young couple wants to have a baby, but they’re worried it’ll carry a disease that runs in the family. “There’s a solution,” the doctor says, “a technology that can alter the disease-causing gene in the egg, ensuring that the baby is born healthy.”
“How about giving our child blue eyes and musical talent?” the parents ask. “I think I can help you,” the doctor says.
Such a conversation once belonged only in the realm of science fiction. But with advances in gene-editing technologies such as CRISPR, fiction might become reality. In 2018, a doctor in China announced that he’d used CRISPR to edit twin girls’ DNA to protect them against the AIDS virus.
But not everyone thinks the world is ready for all the implications of tinkering with human genes. For instance, who’d get to decide which traits should be changed? And aren’t the traits we’re born with part of who we are? In a recent Pew Research Center study, about half of Americans agreed that it was “meddling with nature” and “a line we should...
Related Articles
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By Amy Feldman, Forbes | 02.17.2026
"Jennifer Doudna" by Duncan Hull for the Royal Society via Wikimedia Commons licensed under CC by SA 3.0
Soon after KJ Muldoon was born in August 2024, he was lethargic and wouldn’t eat. His worried doctors realized his ammonia...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...